ANI Pharmaceuticals (ANIP) Stock Price, News & Analysis

+0.52 (+0.79%)
(As of 04/23/2024 ET)
Today's Range
50-Day Range
52-Week Range
85,940 shs
Average Volume
138,397 shs
Market Capitalization
$1.39 billion
P/E Ratio
Dividend Yield
Price Target

ANI Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
21.0% Upside
$80.00 Price Target
Short Interest
0.93% of Shares Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.26mentions of ANI Pharmaceuticals in the last 14 days
Based on 16 Articles This Week
Insider Trading
Selling Shares
$10.36 M Sold Last Quarter
Proj. Earnings Growth
From $3.55 to $4.14 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.74 out of 5 stars

Medical Sector

55th out of 909 stocks

Pharmaceutical Preparations Industry

20th out of 425 stocks

ANIP stock logo

About ANI Pharmaceuticals Stock (NASDAQ:ANIP)

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

ANIP Stock Price History

ANIP Stock News Headlines

Exposed: 10 CENT Crypto to Explode April 20th?
Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than Bitcoin
Evaluating ANI Pharmaceuticals: Insights From 5 Financial Analysts
Exposed: 10 CENT Crypto to Explode April 20th?
Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than Bitcoin
3 Biotech Stocks Gaining Altitude and Interest
ANI Pharmaceuticals Inc
See More Headlines
Receive ANIP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ANI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Confirmed)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Previous Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
4 Analysts


Net Income
$18.78 million
Pretax Margin


Sales & Book Value

Annual Sales
$486.82 million
Cash Flow
$6.48 per share
Book Value
$21.13 per share


Free Float
Market Cap
$1.39 billion
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

ANIP Stock Analysis - Frequently Asked Questions

Should I buy or sell ANI Pharmaceuticals stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ANI Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ANIP shares.
View ANIP analyst ratings
or view top-rated stocks.

What is ANI Pharmaceuticals' stock price target for 2024?

4 analysts have issued 12-month target prices for ANI Pharmaceuticals' shares. Their ANIP share price targets range from $77.00 to $83.00. On average, they expect the company's stock price to reach $80.00 in the next year. This suggests a possible upside of 21.0% from the stock's current price.
View analysts price targets for ANIP
or view top-rated stocks among Wall Street analysts.

How have ANIP shares performed in 2024?

ANI Pharmaceuticals' stock was trading at $55.14 at the beginning of 2024. Since then, ANIP stock has increased by 19.9% and is now trading at $66.14.
View the best growth stocks for 2024 here

Are investors shorting ANI Pharmaceuticals?

ANI Pharmaceuticals saw a decline in short interest in March. As of March 31st, there was short interest totaling 197,000 shares, a decline of 24.7% from the March 15th total of 261,600 shares. Based on an average daily trading volume, of 137,600 shares, the short-interest ratio is presently 1.4 days.
View ANI Pharmaceuticals' Short Interest

When is ANI Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our ANIP earnings forecast

How can I listen to ANI Pharmaceuticals' earnings call?

ANI Pharmaceuticals will be holding an earnings conference call on Friday, May 10th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 800-938-2239 with passcode "4555224".

How were ANI Pharmaceuticals' earnings last quarter?

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) announced its quarterly earnings data on Thursday, February, 29th. The specialty pharmaceutical company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.58 by $0.20. The specialty pharmaceutical company earned $131.65 million during the quarter, compared to analyst estimates of $123.02 million. ANI Pharmaceuticals had a trailing twelve-month return on equity of 18.06% and a net margin of 3.86%.

What guidance has ANI Pharmaceuticals issued on next quarter's earnings?

ANI Pharmaceuticals updated its FY 2024 earnings guidance on Friday, April, 19th. The company provided earnings per share guidance of 4.260-4.670 for the period, compared to the consensus earnings per share estimate of 4.470. The company issued revenue guidance of $520.0 million-$542.0 million, compared to the consensus revenue estimate of $534.2 million.

What is Arthur Przbyl's approval rating as ANI Pharmaceuticals' CEO?

5 employees have rated ANI Pharmaceuticals Chief Executive Officer Arthur Przbyl on Arthur Przbyl has an approval rating of 100% among the company's employees. This puts Arthur Przbyl in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 49.0% of employees surveyed would recommend working at ANI Pharmaceuticals to a friend.

What other stocks do shareholders of ANI Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ANI Pharmaceuticals investors own include Abraxas Petroleum (AXAS), Gilead Sciences (gild), Micron Technology (MU), AbbVie (ABBV), Teva Pharmaceutical Industries (TEVA), Alibaba Group (BABA), Broadcom (AVGO), Cisco Systems (CSCO), Exelixis (EXEL) and Intel (INTC).

Who are ANI Pharmaceuticals' major shareholders?

ANI Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Los Angeles Capital Management LLC (0.12%), Allspring Global Investments Holdings LLC (0.10%), State of Alaska Department of Revenue (0.04%) and BTC Capital Management Inc. (0.04%). Insiders that own company stock include Antonio R Pera, Chad Gassert, James G Marken, Jeanne Thoma, Krista Davis, Meredith Cook, Meridian Venture Partners Ii L, Muthusamy Shanmugam, Nikhil Lalwani, Ori Gutwerg, Patrick D Walsh, Stephen P Carey and Thomas Haughey.
View institutional ownership trends

How do I buy shares of ANI Pharmaceuticals?

Shares of ANIP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ANIP) was last updated on 4/23/2024 by Staff

From Our Partners